We are developing first-in-class investigational therapies that aim to restore immune balance in autoimmune disease and transplantation, offering patients a safer alternative to broad immunosuppression.
Individuals suffering from autoimmune diseases and transplant rejection need safer, more tolerable, and more effective treatments
Our Science
The immune system has its own built-in brakes, natural pathways that keep T cells in check and protect healthy tissue from attack. In autoimmune disease and organ transplant rejection, those brakes fail. Today’s standard treatments respond by broadly suppressing immunity, which can control disease but leaves patients exposed to infection, cancer and long-term toxicity.
Mitera takes a different approach. Our programs build on a newly understood axis of immune regulation that the body uses to keep T cell and B cell activity in check. By harnessing this endogenous pathway, we aim to quiet the specific immune responses that drive disease while preserving the protective immunity patients rely on every day.
We believe this precision approach can restore lasting immune tolerance and change how autoimmune and transplant patients are treated.
Our Focus
Autoimmune kidney disease
Rare autoimmune conditions such as ANCA-associated vasculitis can rapidly destroy kidney function, and current therapies carry serious burdens. We are working toward treatments that control disease activity at its immunological source.
Transplantation
Transplant recipients face a lifetime of immunosuppression to protect their new organ. We are pursuing therapies that could prevent rejection with less of the toxicity and infection risk of today’s regimens.
Beyond
The biology underlying our platform is relevant across a range of T cell–driven autoimmune diseases, and we are actively exploring additional indications.
Credit: NIAID (CC BY 2.0)
A Novel Approach to Immune Tolerance
Mitera is developing first-in-class therapeutic candidates with a novel mechanism of action that works on three fronts at once:
Restrains effector T cells (Teffs), the cells that drive tissue damage
Expands regulatory T cells (Tregs), the immune system’s natural peacekeepers
Dampens B cell activity, reducing B cell activation, proliferation and antibody production
Why three mechanisms matter
Tregs help keep the immune system healthy and balanced, and both transplant recipients and autoimmune patients often have too few of them. But boosting Tregs alone is unlikely to deliver a rapid clinical impact. By acting on Teffs and B cells at the same time, our approach aims to bring the immune system back into balance more quickly and completely.
Inspired by pregnancy
Our recombinant drug candidates are derived from a natural human protein made by the placenta during pregnancy and also abundant in the thymus, where the immune system learns tolerance. Emerging research suggests this protein helps the mother’s immune system accept the developing fetus.
That same principle of tolerance is what transplant and autoimmune patients need. Rejection and autoimmune disease are driven by overactive Teffs and insufficient Treg control, making this protein a compelling starting point for new therapies.
It’s also the inspiration for our name: Mitera comes from the Greek word for mother.
Built on world-class science
Our programs are based on intellectual property exclusively licensed from Cedars-Sinai Medical Center in Los Angeles.
The goal: better options for patients
If successful in clinical studies, our therapies could help patients without the toxicity and immune cell depletion of today’s standard immunosuppressants. We are also exploring this novel axis of immunobiology to develop additional therapeutic programs.
Meet the Team
-
Kevin Chow, PhD
Co-founder, President & CEO
-
Stanley C. Jordan, MD
Co-founder & Chief Scientific Officer
-
S. Ananth Karumanchi, MD
Co-founder & Lead Scientific Advisor
-
Tom Neary
Head of Finance
-
Kristin Mulready, MS, GCEC
Head of Program Management
-
Scott Rudge, PhD
Head of CMC
-
Amanda Kohler, PhD
Head of Protein Engineering
Investor and Business Development Inquiries:
Mitera Biosciences Inc.
3120 139th Avenue Southeast Suite 500
Bellevue, Washington 98005
Phone: +1 (425) 818-5036
Mitera Biosciences’ product candidates are investigational and have not been approved by the U.S. Food and Drug Administration or any other regulatory authority. Their safety and efficacy have not been established. This website contains forward-looking statements that involve risks and uncertainties, and actual results may differ materially.
Copyright © 2026 Mitera Biosciences Inc. All rights reserved.